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EPIDEMIOLOGY/POPULATION SCIENCE
Association of Fatal and Nonfatal Cardiovascular 
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Masahiro Kikuya , Takayoshi Ohkubo , Eamon Dolan, Katarzyna Stolarz-Skrzypek, Qi-Fang Huang , Valérie Tikhonoff ,  
Sofia Malyutina, Edoardo Casiglia , Lars Lind, Edgardo Sandoya , Jan Filipovský, Natasza Gilis-Malinowska,  
Krzysztof Narkiewicz , Kalina Kawecka-Jaszcz, José Boggia , Ji-Guang Wang , Yutaka Imai, Thomas Vanassche,  
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ABSTRACT: Major adverse cardiovascular events are closely associated with 24-hour blood pressure (BP). We determined 
outcome-driven thresholds for 24-hour mean arterial pressure (MAP), a BP index estimated by oscillometric devices. We 
assessed the association of major adverse cardiovascular events with 24-hour MAP, systolic BP (SBP), and diastolic BP 
(DBP) in a population-based cohort (n=11 596). Statistics included multivariable Cox regression and the generalized R2 
statistic to test model fit. Baseline office and 24-hour MAP averaged 97.4 and 90.4 mm Hg. Over 13.6 years (median), 
2034 major adverse cardiovascular events occurred. Twenty-four-hour MAP levels of <90 (normotension, n=6183), 90 to 
<92 (elevated MAP, n=909), 92 to <96 (stage-1 hypertension, n=1544), and ≥96 (stage-2 hypertension, n=2960) mm Hg 
yielded equivalent 10-year major adverse cardiovascular events risks as office MAP categorized using 2017 American 
thresholds for office SBP and DBP. Compared with 24-hour MAP normotension, hazard ratios were 0.96 (95% CI, 0.80–
1.16), 1.32 (1.15–1.51), and 1.77 (1.59–1.97), for elevated and stage-1 and stage-2 hypertensive MAP. On top of 24-hour 
MAP, higher 24-hour SBP increased, whereas higher 24-hour DBP attenuated risk (P<0.001). Considering the 24-hour 
measurements, R2 statistics were similar for SBP (1.34) and MAP (1.28), lower for DBP than for MAP (0.47), and reduced 
to null, if the base model included SBP and DBP; if the ambulatory BP indexes were dichotomized according to the 2017 
American guideline and the proposed 92 mm Hg for MAP, the R2 values were 0.71, 0.89, 0.32, and 0.10, respectively. In 
conclusion, the clinical application of 24-hour MAP thresholds in conjunction with SBP and DBP refines risk estimates. 
(Hypertension. 2021;77:39–48. DOI: 10.1161/HYPERTENSIONAHA.120.14929.) • Data Supplement
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The Global Burden of Disease Study 2010 reported that high blood pressure (BP) is the major modifi-able cardiovascular risk factor, causing 9.4 million 
deaths annually, that is, more than half of cardiovas-
cular mortality.1 Prevention of the cardiovascular com-
plications associated with hypertension requires that 
BP be accurately measured,2 preferably by 24-hour 
ambulatory monitoring.3,4 Because mercury is being 
phased out, oscillometry is replacing the auscultatory 
Korotkoff approach in use since 1910.5 The proprie-
tary software implemented in automated oscillometric 
devices draws an envelope around the pressure oscil-
lations in the brachial cuff and estimates mean arterial 
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maximal oscillations (Figure S1 in the Data Supple-
ment). From the so estimated MAP, the software then 
computes systolic and diastolic BP.6,7 For validated 
devices, the fault tolerance around the calculated sys-
tolic and diastolic BP is ±5 mm Hg.8 Furthermore, MAP 
is similar throughout the arterial tree,9 thereby avoiding 
the dilemma as to whether central compared with bra-
chial BP confers higher cardiovascular risk.10 In addi-
tion, MAP captures risk-related information associated 
with both systolic and diastolic BP.11 In an individual 
participant meta-analysis of 1 million people, office 
MAP was a better predictor of vascular mortality than 
systolic or diastolic BP or pulse pressure.12 However, 
to our knowledge, hypertension guidelines do not 
propose how MAP should be used for risk stratifica-
tion.3,4 We recently demonstrated that of all in-office 
and ambulatory BP indexes the association of mortality 
and cardiovascular complications was closest with the 
24-hour ambulatory BP.13 Given the clinical underuse 
of MAP and the predictive superiority of 24-hour BP,13 
we established in a population-based cohort of 11 596 
adults, recruited in Europe, Asia, and South America, 
outcome-driven thresholds for 24-hour MAP that might 
guide clinical practice and we assessed the strength of 
its associations with fatal and nonfatal cardiovascular 
end points.
METHODS
The International Database on Ambulatory Blood Pressure in 
Relation to Cardiovascular Outcome data and the SAS pro-
grams written for the present analysis will not be made avail-
able to other researchers because participant-level data sharing 
was not covered by the informed consent and because this 
option is not in compliance with the General Data Protection 
Act (EU Directive 2016/680). However, any scientifically 
motivated request, submitted to the study coordinator (J.A. 
Staessen), to run additional analyses on the data set used in 
the current article, will be implemented if only summary statis-
tics are requested.
Study Participants
All population studies included in the International Database 
on Ambulatory Blood Pressure in Relation to Cardiovascular 
Outcome13,14 received ethical approval from the Institutional 
Review Boards in their country of origin and adhered to the 
principles of the Declaration of Helsinki.15 Participants pro-
vided informed written consent. The International Database 
on Ambulatory Blood Pressure in Relation to Cardiovascular 
Outcome database, constructed and maintained in Leuven, 
did not include any data allowing identification of individuals. 
In line with national regulations, Review Boards either waived 
or provided ethical clearance for the secondary use of data to 
be included in the International Database on Ambulatory Blood 
Pressure in Relation to Cardiovascular Outcome resource. 
Population studies qualified for inclusion, if office and ambula-
tory BP and cardiovascular risk factors had been measured at 
baseline and if follow-up included both fatal and nonfatal out-
comes. Across all studies, enrollment took place from August 
1985 until May 2010 (Table S1). Baseline refers to the date 
of the first BP measurement, ranging across cohorts from May 
1985 until May 2010; the last follow-up data were collected 
from August 2007 to October 2016. Table S2 provides the lit-
erature sources describing the design characteristics of the 13 
studies (references 1–25 in the Data Supplement).
Nonstandard Abbreviations and Acronyms
BP blood pressure
DBP diastolic BP




• We established in a population-based cohort of 11 596 
adult people outcome-driven thresholds for 24-hour 
mean arterial pressure (MAP), and we assessed its 
associations with fatal and nonfatal cardiovascular end 
points.
What Is Relevant?
• Using a composite cardiovascular end point as primary 
outcome and the 10-year risks associated with 2017 
American College of Cardiology/American Heart 
Association thresholds for office blood pressure (BP) 
as reference, we established levels of 24-hour MAP of 
<90, ≥90 to <92, ≥92 to <96, and ≥96 mm Hg delin-
eated normotension, elevated 24-hour MAP, stage 
1 hypertension, and stage 2 combined with severe 
hypertension, respectively.
• Combined with 24-hour systolic BP and diastolic BP, 
24-hour MAP kept its prognostic accuracy in categori-
cal and continuous analyses of BP.
Summary
Our observations have implications for hypertension 
management and the use and validation of oscillomet-
ric BP measuring devices. Oscillometric BP measuring 
devices should include MAP in the reports they gener-
ate. Considering 24-hour MAP in clinical practice in 
conjunction with 24-hour systolic BP and diastolic BP 
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BP Measurements
Nurses or physicians measured office BP with a standard 
mercury sphygmomanometer or with validated auscultatory or 
oscillometric devices. The office BP was the average of 2 con-
secutive readings. MAP on office measurement was diastolic 
BP plus one-third of pulse pressure (the difference between 
systolic and diastolic BP) and categorized according to the 
2017 American guidelines for systolic and diastolic pressure,3 
rounded to the closest integer. The cut off points were <93 
mm Hg for normotension ([80+0.33]×[120–80]) mm Hg; 93 to 
<97 mm Hg for elevated BP; 97 to <107 mm Hg for stage-1 
hypertension, ≥107 mm Hg for stage-2 hypertension combined 
with severe hypertension. Hypertension was an office BP of 
≥130 mm Hg systolic or ≥80 mm Hg diastolic or use of antihy-
pertensive drugs.3
For ambulatory monitoring (Table S3), portable oscillometric 
monitors were programmed to obtain readings at 30-minute 
intervals throughout the whole day or at intervals of 15 to 30 
minutes during daytime and at intervals ranging from 20 to 60 
minutes during nighttime. Ambulatory recordings had to include 
at least 6 daytime and 3 nighttime readings.16
Ascertainment of End Points
We ascertained vital status and the incidence of fatal and 
nonfatal end points from the appropriate sources in each 
country. Prespecified end points were coded according to 
the International Classification of Diseases (Table S4). The 
primary end point was a composite cardiovascular outcome 
consisting of cardiovascular mortality, including sudden 
death, nonfatal coronary events, coronary revascularization, 
heart failure, and stroke. Secondary end points included 
total mortality, cardiovascular mortality, fatal and nonfatal 
coronary end points, and fatal and nonfatal stroke exclud-
ing transient ischemic attack. The diagnosis of heart fail-
ure required hospitalization in the 2 Scandinavian cohorts 
(Table S4). In the other cohorts, it was a clinical diagno-
sis or the diagnosis on the death certificate. All end points 
were validated against hospital files or medical records held 
by primary care physicians, specialists, or hospitals. In all 
outcome analyses, only the first event within each category 
was considered. Participants free of events were censored 
at last follow-up.
Statistical Analysis
For database management and statistical analysis, we used 
SAS software, version 9.4, maintenance level 5. We applied 
the Kolmogorov-Smirnov test for assessing the normality of 
distributions. For between-group comparison of means and 
proportions, we applied the large-sample z-test and Fisher 
exact test, respectively. After stratification for cohort and 
sex, we interpolated missing values of body mass index and 
total serum cholesterol from the regression slopes on age. In 
participants with unknown status of smoking, drinking, dia-
betes, or history of cardiovascular disease, we set the indica-
tor (dummy) variable to the cohort- and sex-specific mean of 
the codes (0, 1).
In multivariable-adjusted Cox regression, we accounted 
for cohort (random effect), sex, and baseline characteris-
tics including age, body mass index, smoking and drinking, 
serum cholesterol, antihypertensive drug intake, history of 
cardiovascular disease, and diabetes. To adjust for cohort, 
we pooled participants recruited in the framework of the 
European Project on Genes in Hypertension (Gdańsk, 
Kraków, Novosibirsk, Padova, and Pilsen; Table S1). We 
checked the proportional hazards assumption by the 
Kolmogorov-type supremum test and by testing the interac-
tion between BP and follow-up time.
We obtained operational thresholds for MAP by ambula-
tory monitoring in 5 steps.14 First, we computed the 10-year 
incidence rates of end points associated with office MAP, 
using as thresholds 93, 97, and 107 mm Hg. Second, we com-
puted the 10-year risk of end points associated with ambula-
tory MAP ranging from the 10th up to the 90th percentile, 
using intervals of 2 mm Hg. In a third step, we selected the 
ambulatory MAP levels that were associated with similar 
10-year risks as the office MAP thresholds. Next, we calcu-
lated the bootstrap distribution of the so obtained ambulatory 
MAP thresholds by randomly resampling the study population 
1000× with replacement. For each new sample, we repeated 
the first 3 steps, while accounting for tied event times. Finally, 
we calculated the bootstrap point estimates and 95% CIs of 
the ambulatory MAP thresholds as the mean±1.96 SEs of the 
bootstrap distribution.
Based on the thresholds for the 24-hour MAP obtained by 
the bootstrap procedure, we computed incidence rates and 
multivariable-adjusted hazard ratios as metrics of absolute and 
relative risk, respectively. Rates were standardized by the direct 
method for cohort, sex and age (<40, 40 to <60, and ≥60 
years) and 95% CIs were computed as R R/N± ×1 96. ( ),  
where R and N are the rate and the number of individuals used 
to compute the rate. We constructed heat maps to visualize the 
contribution of 24-hour systolic, diastolic, and 24-hour MAP to 
the association with the primary end point. Improvement in the 
fit of nested Cox models was assessed by the log likelihood 
ratio and the generalized R2 statistic.17 Statistical significance 
was a 2-tailed α-level of 0.05 or less.
RESULTS
Baseline Characteristics
Of 13 728 people included in the database, we excluded 
2132, because they were adolescents younger than 18 
years (n=317), because their office BP or use of anti-
hypertensive drugs had not been recorded at baseline 
(n=255), or because their ambulatory BP recording 
included fewer readings than required (n=1560). This 
left 11 596 individuals for statistical analysis (Table 1). 
Missing values of body mass index (n=34), serum cho-
lesterol (n=903), smoking (n=96), diabetes (n=5), and 
history of cardiovascular disease (n=1) were interpolated 
or set to the cohort- and sex-specific means. Table 1 lists 
the baseline characteristics of the participants. Mean age 
at enrollment was 52.8 years. Across increasing fourths 
(quartiles) of the 24-hour MAP distribution (Table S5), 
the percentage of women decreased while the preva-
lence of hypertension and diabetes increased as well as 
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index, serum cholesterol, and blood glucose (P value for 
linear trend <0.001).
Office and Ambulatory BP
On office measurement, systolic/diastolic BP averaged 
132.6/79.8 mm Hg, and MAP 97.4 mm Hg (Table 1). The 
median number of ambulatory readings recorded over 
24-hour was 55 (5th–95th percentile interval, 33–82), 
ranging across cohorts (Table S3) from 37 (5th–95th 
percentile interval, 26–42) to 80 (5th–95th percentile 
interval, 67–83). On 24-hour monitoring, systolic/dia-
stolic BP averaged 123.6/73.9 mm Hg, and MAP 90.4 
mm Hg (Table 1). All BP measurements were highly cor-
related (Table S6; P<0.0001).
24-Hour MAP Thresholds
In all Cox regression models that follow, the proportional 
hazard assumption was met. The number of person-years 
of follow-up totaled 158 431 in 11 596 participants. Over a 
median follow-up of 13.6 years (5th–95th percentile inter-
val, 3.6–26.0), 2034 primary end points occurred, includ-
ing 916 (45.0%) coronary end points, and 809 (39.8%) 
strokes. Over the same time span, 2821 participants died, 
1059 (37.5%) of cardiovascular disease (Table S4). Using 
the bootstrap procedure (Table 2), we obtained as thresh-
olds for 24-hour MAP: <90 mm Hg (normotension); 90 to 
<92 mm Hg (elevated MAP); 92 to <96 mm Hg (stage-1 
hypertension), and ≥96 mm Hg (stage-2 combined with 
severe hypertension; henceforth referred to as stage-2 
hypertension). The corresponding thresholds for daytime 
and nighttime MAP were 94/80 mm Hg, 96/82 mm Hg, 
and 104/88 mm Hg for elevated, stage 1 and stage 2 
hypertension, respectively. The thresholds based on the 
full data set were similar to the means of the bootstraps. 
In sensitivity analyses, rounded thresholds were 2 mm Hg 
lower in women than in men, and among participants with 
a previous history of cardiovascular diseases (Table S7). 
However, the thresholds remained largely consistent using 
16/6 or 11/5 for the number of daytime/nighttime read-
ings, in participants untreated or treated for hypertension 
at baseline, in patients with or without diabetes at base-
line (Table S7), after excluding one cohort at a time (Table 
S8), and in Europeans compared with Asians and South 
Americans (Table S9).
Absolute Risk Associated With 24-Hour MAP
Based on the aforementioned MAP thresholds, the 
primary end point occurred in 715 of 6183 normoten-
sive participants (11.6%; rate per 1000 person-years, 
11.9 [95% CI, 11.1–13.2]); in 134 of 909 people with 
elevated BP (14.7%; 11.3 [9.5–13.6]); in 312 of 1544 
participants with stage-1 hypertension (20.2%; 15.2 
[13.5–17.2]); and in 873 of 2960 stage-2 hypertensive 
patients (29.5%; 21.5 [20.0–23.3]). The increase in 
absolute risk across higher MAP categories was highly 
significant (P<0.001). This was also the case for the 
secondary end points (Table S10).
Relative Risk Associated With 24-Hour MAP
Compared with the normotensive reference group 
(Table 3), the relative risk of a primary end point asso-
ciated with 24-hour MAP was 32% higher in patients 
with stage-1 hypertension and 77% higher in those 
with stage-2 hypertension (P<0.001). For the second-
ary end points, the corresponding risk estimates ranged 
Table 1. Baseline Characteristics of Participants
Characteristics Statistic (n=11 596)
Participants with characteristics
 Women, n (%) 5754 (49.6)
 Europeans, n (%) 7096 (61.2)
 Asians, n (%) 2181 (18.8)
 South Americans, n (%) 2319 (20.0)
 Current smoking, n (%)*† 3150 (27.2)
 Drinking alcohol, n (%)*‡ 6006 (51.8)
 Office hypertension, n (%)§∥ 7424 (64.1)
  On antihypertensive treatment, n (%)* 2273 (19.6)
 Diabetes, n (%)¶ 885 (7.6)
 History of cardiovascular disease, n (%)* 1287 (11.1)
Mean (±SD) of characteristics
 Age, y 52.8±15.9
 Body mass index, kg/m2# 25.4±4.4
 Office systolic blood pressure, mm Hg∥ 132.6±23.4
 Office diastolic blood pressure, mm Hg∥ 79.8±12.1
 Office mean arterial pressure, mm Hg∥ 97.4±14.5
 Twenty-four hour systolic blood pressure, mm Hg** 123.6±14.4
 Twenty-four hour diastolic blood pressure, mm Hg** 73.9±8.7
 Twenty-four hour mean arterial pressure, mm Hg** 90.4±8.2
 Twenty-four hour heart rate, beats per minute 72.5±9.2
 Serum cholesterol, mg/dL†† 212.8±43.7
 Blood glucose, mg/dL†† 94.3±26.4
*Assessed by questionnaire or interview at baseline.
†Use of smoking materials on a daily basis.
‡Occasional or daily consumption of alcoholic beverages.
§An office blood pressure of ≥130 mm Hg systolic or ≥80 mm Hg diastolic, or 
use of antihypertensive drugs.
∥Office blood pressure was measured using mercury sphygmomanometers or 
validated auscultatory or oscillometric devices. Mean arterial pressure was dia-
stolic blood pressure plus one-third of pulse pressure (the difference between 
systolic and diastolic blood pressure).
¶Use of antidiabetic drugs, fasting blood glucose of ≥126 mg/dL (7.0 
mmol/L), random blood glucose of ≥200 mg/dL (11.1 mmol/L), a self-reported 
diagnosis, or diabetes documented in practice or hospital records.
#Body weight in kilogram divided by body height in meters squared.
**Twenty-four hour blood pressure was measured with validated oscillometric 
devices (see Table S3 in the Data Supplement).
††Serum cholesterol and blood glucose were measured by automated meth-
ods in certified laboratories. Conversion factors: to convert cholesterol to mmol/L, 
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from 16% to 52% for stage-1 hypertension (P≤0.173 to 
<0.010) and from 39% to 90% for stage-2 hypertension 
(P<0.001). These findings were direction wise consis-
tent in 6996 participants younger than 60 years and in 
4600 patients aged 60 years or more (Table 3), albeit 
that in the younger age group the relative risk of cardio-
vascular mortality and coronary end points was formally 
significant only in patients with stage-2 hypertension 
(P<0.001). The interaction terms between age and the 
24-hour MAP categories were nonsignificant (Table 3).
Association of the Primary End point With MAP, 
Systolic and Diastolic BP
We stratified the analysis of 24-hour MAP by the median 
of the MAP distribution (90 mm Hg). In 2-mm Hg steps, 
hazard ratios were computed for lower and higher MAP 
levels with as reference group participants with levels 
of 90 mm Hg or more or <90 mm Hg, respectively. In 
line with the data in Table 2, the risk of the primary end 
point (Figure 1A) increased above unity at a level of ≈92 
mm Hg. Using the American College of Cardiology/Amer-
ican Heart Association thresholds for 24-hour systolic/
diastolic BP (<125/<75 versus ≥125/≥75 mm Hg) and 
the presently obtained thresholds for 24-hour MAP (<92 
versus ≥92 mm Hg; Table 2), the 11 596 participants 
were subdivided in 4 groups. For systolic combined with 
MAP, 6284 people (54.2%) were normotensive for both 
BP indexes (group A), 808 (7.0%) had high systolic BP 
but normal MAP (group B), 585 (5.0%) had normal sys-
tolic BP but elevated MAP (group C), and 3919 (33.8%) 
had both elevated systolic BP and MAP (group D). For 
cross-classification with diastolic BP, these numbers 
were 6427 (55.4%), 665 (5.7%), 518 (4.5%), and 3986 
(34.4%), respectively. In multivariable-adjusted analyses 
with group A as reference, the relative risk was similar in 
systolic/diastolic groups B (+8%/−8%; P≥0.317; Fig-
ure 1B and 1C) but elevated in group C (+34%/+46%; 
P≤0.027) and in group D (+71%/+64%; P<0.001).
Heat maps combining 24-hour systolic, diastolic and 
MAP (Figure 2) showed along the horizontal axis that 
the 10-year risks of the primary end point increased with 
higher MAP (P<0.001). Along the vertical axis, higher 
systolic BP (Figure 2C; P<0.001) added to the risk con-
ferred by MAP, whereas higher diastolic BP attenuated 
the risk (Figure 2D; P<0.001). Combined with MAP, 
24-hour pulse pressure added to the risk conferred 
by MAP (Figure S2), replicating the results for systolic 
BP (Figure 2C). Finally, we assessed the log likelihood 
ratios and generalized R2 statistics across nested mod-
els. The associations of the primary end point with MAP 
and systolic BP, both analyzed as continuous variables, 
were similar if the base model included the covariables 
accounted for in adjusted analyses (R2, 1.34 and 1.28, 
Table 2. Ambulatory MAP Thresholds Yielding Equivalent 10-y Risk Compared With the Reference Thresholds of Office MAP 
in 11 596 Participants
End points
Reference office MAP* thresh-
olds and associated 10-y risk†
Ambulatory MAP* thresholds yielding equivalent 10-y risk




Risk in percent 





2034 93 4.55 (4.09–5.00) 89.4 (88.5–90.3) 93.4 (92.2–94.6) 79.3 (78.1–80.5) 90 94 80
 97 4.81 (4.35–5.27) 91.5 (90.9–92.0) 96.1 (95.5–96.8) 81.7 (80.9–82.4) 92 96 82
 107 5.54 (5.04–6.04) 96.6 (95.9–97.3) 103.1 (102.1–104.1) 87.6 (86.7–88.4) 96 104 88
Total mortality 2821 93 3.75 (3.38–4.12) 89.4 (87.9–90.8) 92.7 (89.9–95.4) 80.2 (78.8–81.6) 90 92 80
 97 3.86 (3.49–4.24) 91.5 (90.7–92.3) 96.0 (94.6–97.3) 82.1 (81.3–82.9) 92 96 82
 107 4.17 (3.76–4.59) 96.7 (95.5–97.9) 104.1 (101.7–106.6) 86.9 (85.7–88.2) 96 104 86
Cardiovascular 
mortality
1059 93 1.12 (0.91–1.33) 90.4 (88.9–91.9) 94.2 (91.9–96.5) 80.7 (79.0–82.5) 90 94 80
 97 1.18 (0.96–1.40) 92.4 (91.4–93.4) 96.9 (95.4–98.5) 82.9 (81.7–84.1) 92 96 82
 107 1.36 (1.11–1.62) 97.3 (96.4–98.3) 103.8 (102.6–105) 88.2 (87.1–89.3) 96 104 88
Coronary end 
points
916 93 2.17 (1.84–2.49) 89.3 (87.5–91.1) 93.3 (90.7–95.8) 79.7 (77.6–81.8) 90 94 80
 97 2.25 (1.92–2.57) 91.1 (90.2–91.9) 95.7 (94.5–96.9) 81.6 (80.5–82.7) 92 96 82
 107 2.45 (2.09–2.81) 95.5 (93.9–97.2) 101.7 (99.4–104.1) 86.4 (84.6–88.3) 96 102 86
Stroke 809 93 1.71 (1.45–1.97) 89.5 (88.2–90.8) 93.5 (91.9–95.1) 79.2 (77.6–80.8) 90 94 80
 97 1.85 (1.57–2.13) 91.7 (90.9–92.5) 96.4 (95.5–97.3) 81.8 (80.7–82.8) 92 96 82
 107 2.26 (1.92–2.61) 97.3 (96.5–98.1) 103.8 (102.7–104.9) 88.3 (87.3–89.2) 96 104 88
MAP indicates mean arterial pressure.
*MAP was estimated from office blood pressure (MAP=diastolic blood pressure plus one-third of the difference between systolic and diastolic blood pressure) or 
estimated using oscillometric ambulatory monitors. Oscillometric devices compute systolic and diastolic blood pressure, using proprietary algorithms (Figure S1 in the 
Data Supplement).
†The ambulatory MAP thresholds were computed by bootstrapping 1000× multivariable-adjusted Cox models.
‡Proposed thresholds were obtained by rounding the point estimates to the closest even integer value, except for the risk of cardiovascular mortality and stroke events 
associated with 24-h MAP stage 2 combined with severe hypertension, which were set at 96 mm Hg instead of 98 mm Hg for reasons of consistency and precaution.D
ow
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respectively; Table S11). For MAP added to the covari-
ables and diastolic BP, the R2 was 0.47. If the base model 
included the covariables and both systolic and diastolic 
BP, continuous MAP did not add to the model fit (Table 
S11). If MAP and systolic and diastolic BP were dichoto-
mized as in Figure 1B, the corresponding R2 values were 
0.71, 0.89 0.32, and 0.10, respectively (Table S12).
DISCUSSION
Using a composite cardiovascular end point as primary 
outcome, statistical methods published before,14 and 
the 10-year risks associated with the 2017 ACC/AHA 
thresholds for office BP as reference,3 we computed 
thresholds for 24-hour MAP. We focused on 24-hour 
ambulatory BP derived thresholds because we recently 
demonstrated that of all in-office and ambulatory BP 
indexes, mortality and fatal combined with nonfatal car-
diovascular end points were closely associated with the 
24-hour BP level.13 Levels of 24-hour MAP of <90, 90 
to <92, 92 to<96, and ≥96 mm Hg delineated normo-
tension, elevated 24-hour MAP, stage-1 hypertension, 
and stage-2 combined with severe hypertension, respec-
tively. With higher 24-hour MAP categories, both the 
absolute and relative risks of adverse events increased, 
as captured by the incidence and hazard ratios, respec-
tively. These observations withstood multiple sensitivity 
analyses and held true for the primary and secondary 
end points. Combined with 24-hour systolic and diastolic 
BP, 24-hour MAP kept its prognostic accuracy in cat-
egorical and continuous analyses of BP.
Table 3. Association of End Points With 24-h Mean Arterial Pressure Categories
End points category of 
mean arterial pressure
All ages N=11 596 <60 y N=6996 ≥60 y N=4600
E/AR* HR† (95% CI)† P value E/AR* HR (95% CI)†‡ P value E/AR* HR (95% CI)†‡ P value
Primary end point
 Normotension 715/6183   153/4308   562/1875   
 Elevated 134/909 0.96 (0.80–1.16) 0.674 28/537 1.25 (0.83–1.89) 0.282 106/372 0.89 (0.72–1.10) 0.266
 Stage-1 hypertension 312/1544 1.32 (1.15–1.51) <0.001 52/799 1.36 (0.98–1.88) 0.067 260/745 1.29 (1.11–1.50) 0.001
 Stage-2 and severe 
hypertension
873/2960 1.77 (1.59–1.97) <0.001 152/1352 2.14 (1.67–2.75) <0.001 721/1608 1.69 (1.50–1.90) <0.001
Secondary end points
 Total mortality
 Normotension 1107/6183   199/4308   908/1875   
 Elevated 215/909 0.99 (0.85–1.15) 0.883 35/537 1.24 (0.86–1.78) 0.259 180/372 0.95 (0.81–1.12) 0.542
 Stage-1 hypertension 450/1544 1.17 (1.05–1.31) 0.005 65/799 1.25 (0.93–1.67) 0.137 385/745 1.16 (1.03–1.31) 0.016
 Stage-2 and severe 
hypertension
1049/2960 1.39 (1.27–1.53) <0.001 144/1352 1.80 (1.42–2.28) <0.001 905/1608 1.34 (1.21–1.47) <0.001
Cardiovascular mortality
 Normotension 358/6183   45/4308   313/1875   
 Elevated 62/909 0.85 (0.65–1.12) 0.248 7/537 1.04 (0.46–2.33) 0.932 55/372 0.83 (0.62–1.11) 0.203
 Stage-1 hypertension 165/1544 1.31 (1.09–1.59) 0.005 16/799 1.32 (0.73–2.38) 0.358 149/745 1.31 (1.08–1.60) 0.007
 Stage-2 and severe 
hypertension
474/2960 1.84 (1.59–2.13) <0.001 53/1352 2.53 (1.63–3.93) <0.001 421/1608 1.77 (1.52–2.07) <0.001
Coronary end points
 Normotension 322/6183   80/4308   242/1875   
 Elevated 64/909 1.00 (0.76–1.32) 0.978 18/537 1.47 (0.86–2.50) 0.155 46/372 0.88 (0.64–1.22) 0.445
 Stage-1 hypertension 132/1544 1.16 (0.94–1.42) 0.173 29/799 1.32 (0.85–2.05) 0.213 103/745 1.12 (0.88–1.41) 0.360
 Stage-2 hypertension 398/2960 1.58 (1.35–1.86) <0.001 87/1352 2.22 (1.58–3.12) <0.001 311/1608 1.44 (1.20–1.72) <0.001
Stroke
 Normotension 278/6183   57/4308   221/1875   
 Elevated 41/909 0.74 (0.53–1.03) 0.076 7/537 0.87 (0.39–1.93) 0.734 34/372 0.71 (0.50–1.03) 0.070
 Stage-1 hypertension 135/1544 1.52 (1.23–1.88) <0.001 24/799 1.90 (1.16–3.14) 0.012 111/745 1.43 (1.14–1.81) 0.002
 Stage-2 and severe 
hypertension
355/2960 1.90 (1.60–2.24) <0.001 43/1352 1.67 (1.07–2.59) 0.023 312/1608 1.93 (1.61–2.32) <0.001
BP indicates blood pressure; and HR, hazard ratio.
*E/AR denotes the number of end points/number of participants at risk.
†HR, given with 95% CI describe the relative risk compared with normotensive participants. HRs were adjusted for cohort (random effect), sex, and baseline charac-
teristics including age, body mass index, smoking and drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes.
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The fit of the associations of the primary end point 
with MAP and systolic BP, both analyzed as continuous 
variables, were similar if the base model included only 
the covariables accounted for in adjusted analyses, but 
if the base model also included systolic and diastolic BP, 
continuous MAP did no longer add to the model fit (Table 
S11). These observations are in line with the concept that 
diastolic BP is the main determinant of MAP and that 
MAP captures information related to both systolic and 
diastolic BP. If the BP indexes were dichotomized, using 
the ACC/AHA thresholds for systolic (125 mm Hg) and 
diastolic (75 mm Hg) BP and the outcome-driven MAP 
threshold derived in this article (92 mm Hg), MAP did 
add to a model including covariables and both systolic 
and diastolic BP thresholds. The log likelihood ratios and 
generalized R2 statistics only evaluate model fit but not 
the strength of the association of an end point with a BP 
index, as shown in Figure 2. As demonstrated by numer-
ous placebo and actively controlled trials18 and long-term 
cohort studies of populations13 and patients,19 BP is the 
overriding modifiable cardiovascular risk factor. Small 
increments in R2 challenge this concept. However, major 
irreversible risk factors, such as sex and age, on their own 
already generate an R2 of 23.94%. Consequently, adding 
BP to multivariable-adjusted models that already account 
for sex, age, and other risk factors cannot substantially 
augment R2. Under such conditions, many researchers 
share the opinion that markers of model fit are imprecise 
and that clinical relevance is of greater importance than 
the improvement of the model fit.20
From a physiological point of view, BP and blood flow 
can be broken down into a pulsatile component with sys-
tolic and diastolic BP representing the extremes of the 
BP oscillations around MAP, which drives organ perfu-
sion.21 When peripheral resistance increases by rarefac-
tion or remodeling of arterioles, MAP rises with parallel 
increments in systolic and diastolic BP. However, when 
there is an additional reduction of arterial compliance, as 
occurs with stiffening of the large arteries, both systolic 
BP and MAP increase¸ whereas diastolic BP decreases.22 
Figure 2 illustrates these concepts, showing that the 
10-year risk of the primary end point was consistently 
greater with higher MAP with an additional contribution 
of systolic BP, whereas higher diastolic BP attenuated 
the risk. Diastolic BP is within 2 mm Hg similar through-
out the arterial system.9 Pulse pressure is the difference 
between systolic and diastolic BP. These hemodynamic 
principles explain why adding systolic BP (Figure 2C) or 
pulse pressure (Figure S2), which both reflect the pulsa-
tile component of BP, produced similar results.
The clinical relevance of our study pertains to the con-
sideration of MAP for identifying hypertension and cat-
egorizing individuals according to their risk for adverse 
health outcomes. As reported before,1,23 relative risk was 
higher at young than older age, whereas absolute fol-
lowed the opposite trend (Table 3). Our observations 
have implications for hypertension management and the 
use and validation of oscillometric BP measuring devices. 
Treatment wise, targeting lower systolic BP goals24 is 
Figure 1. Multivariable-adjusted hazard ratios (HRs; 95% CI) for 
the primary end point in relation to 24-h blood pressure (BP).
A, The analysis was stratified by the median (90 mm Hg) of mean 
arterial pressure (MAP). HRs were computed comparing participants 
with MAP ≤80, ≤82, ≤84, ≤86, or ≤88 with those with MAP >90 
mm Hg and comparing participants with MAP ≥92, ≥94, ≥96, ≥98, 
≥100, or ≥102 with those with MAP <90 mm Hg. Hazard ratios were 
adjusted for cohort (random effect), sex, and baseline characteristics 
including age, body mass index, smoking and drinking, serum 
cholesterol, antihypertensive drug intake, history of cardiovascular 
disease, and diabetes. Vertical bars denote 95% CIs. This plot 
confirmed the increase in risk when MAP was ≥92 mm Hg. B and C, 
The 11 596 participants were subdivided according the American 
College of Cardiology/American Heart Association thresholds for 
24-h systolic BP (SBP) and diastolic BP (DBP) and the calculated 
24-h MAP thresholds (Table 2). The multivariable-adjusted HRs, 
given with 95% CI, represent the risk of a primary end point with 
normotension for SBP and MAP (B) or normotension for diastolic 
and MAP (C) as reference. E/AR indicates number of participants 
with a primary end point/number of participants at risk; and NT/HT, 
normotension/hypertension, and E/AR number of participants with a 
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likely to reduce risk, but only when MAP and diastolic 
BP are not lowered below levels required for the perfu-
sion of the cerebrovascular,25 coronary,26 and renal24 vas-
cular beds. Oscillometric BP measuring devices should 
include MAP in the reports they generate, as this infor-
mation might carry clinical information.
Strengths and Limitations
Generalizability is among the strengths of our study. Par-
ticipants were randomly recruited from populations in 12 
countries and 3 continents. End points were collected 
over a median of 13.6 years of follow-up and encom-
passed both fatal and nonfatal events all adjudicated 
against the source documents available in each country. 
Notwithstanding these strengths, our study must also be 
interpreted within the context of its possible limitations. 
Asians and South Americans were under-represented. We 
had no information on Black people of African descent or 
Black people born and living in Africa, who generally are 
more susceptible to the complications of hypertension.27 
Our findings were obtained in participants aged 18 years 
without upper age limit. They are obviously not applicable 
in children and young adolescents. Finally, we assessed 
Figure 2. Heat maps depicting the 10-y risk of a primary end point in relation to 24-h mean arterial, systolic and diastolic BP in 
11 596 participants.
Numbers in the (A) and (B) grids represent the percentage of participants within each BP cross-classification category; numbers in (C) and (D) 
represent the 10-y risks. Heat maps were derived by Cox proportional hazards regression with systolic BP (C) or diastolic BP (D) plotted along 
the vertical axis and mean arterial pressure (MAP) along the horizontal axis. Estimates of the 10-y risk were standardized to the average of the 
distributions in the whole study population (mean or ratio) of all covariables. Higher MAP consistently conferred greater risk (P<0.001) with an 









Melgarejo et al Risk Associated With Mean Arterial Pressure
Hypertension. 2021;77:39–48. DOI: 10.1161/HYPERTENSIONAHA.120.14929 January 2021  47
model performance by the R2 statistic (Table S12). BP is 
the major modifiable risk factor. The R2 statistic is not a 
very sensitive metric, when the base model, as was the 
case in the current study, performed already well.
Perspectives
When using oscillometric devices for 24-hour BP moni-
toring, <90, 90 to <92, 92 to<96, and ≥96 mm Hg are the 
outcome-driven thresholds for 24-hour MAP, delineating 
normotension, elevated BP and stage-1, and stage-2 
combined with severe hypertension. Adopting 24-hour 
MAP in clinical practice in conjunction with 24-hour sys-
tolic and diastolic BP might refine risk estimates (Fig-
ure 2) and increase awareness that overtreatment of BP 
potentially confers risk, if the perfusion pressure of vital 
organs is lowered too much.24–26
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